These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants. Roberts JK; Stockmann C; Constance JE; Stiers J; Spigarelli MG; Ward RM; Sherwin CM Clin Pharmacokinet; 2014 Jul; 53(7):581-610. PubMed ID: 24871768 [TBL] [Abstract][Full Text] [Related]
4. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898 [TBL] [Abstract][Full Text] [Related]
5. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183 [TBL] [Abstract][Full Text] [Related]
6. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. Gumbo T Curr Opin Infect Dis; 2007 Dec; 20(6):587-91. PubMed ID: 17975408 [TBL] [Abstract][Full Text] [Related]
7. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193 [TBL] [Abstract][Full Text] [Related]
8. Selecting antibiotics based on pharmacokinetic and pharmacodynamic principles. Klutman NE Pharm Pract Manag Q; 1996 Jul; 16(2):9-12. PubMed ID: 10161616 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. McKinnon PS; Paladino JA; Schentag JJ Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273 [TBL] [Abstract][Full Text] [Related]
10. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460 [TBL] [Abstract][Full Text] [Related]
11. Exploration of once-daily dosing of aminoglycosides through Bayesian simulation. Garrelts JC Pharmacotherapy; 1996; 16(2):286-94. PubMed ID: 8820474 [TBL] [Abstract][Full Text] [Related]
12. New dosing strategies for antibacterial agents in the neonate. de Hoog M; Mouton JW; van den Anker JN Semin Fetal Neonatal Med; 2005 Apr; 10(2):185-94. PubMed ID: 15701583 [TBL] [Abstract][Full Text] [Related]
13. Determination of extended-interval gentamicin dosing for neonatal patients in developing countries. Darmstadt GL; Hossain MM; Jana AK; Saha SK; Choi Y; Sridhar S; Thomas N; Miller-Bell M; Edwards D; Aranda J; Willis J; Coffey P Pediatr Infect Dis J; 2007 Jun; 26(6):501-7. PubMed ID: 17529867 [TBL] [Abstract][Full Text] [Related]
14. Suboptimal aminoglycoside dosing in critically ill patients. Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371 [TBL] [Abstract][Full Text] [Related]
15. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Drusano GL Scand J Infect Dis Suppl; 1990; 74():235-48. PubMed ID: 2097712 [TBL] [Abstract][Full Text] [Related]
16. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections. Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target. Bhongsatiern J; Stockmann C; Roberts JK; Yu T; Korgenski KE; Spigarelli MG; Desai PB; Sherwin CM Ther Drug Monit; 2015 Dec; 37(6):756-65. PubMed ID: 26562817 [TBL] [Abstract][Full Text] [Related]
18. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Lodise TP; Lomaestro BM; Drusano GL; Pharmacotherapy; 2006 Sep; 26(9):1320-32. PubMed ID: 16945055 [TBL] [Abstract][Full Text] [Related]
19. Role of pharmacokinetics and pharmacodynamics: does the dose matter? MacGowan AP Clin Infect Dis; 2001 Sep; 33 Suppl 3():S238-9. PubMed ID: 11524725 [TBL] [Abstract][Full Text] [Related]
20. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Roberts JA; Lipman J Clin Pharmacokinet; 2006; 45(8):755-73. PubMed ID: 16884316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]